CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
This Quarter Return
+11.72%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$249M
AUM Growth
+$249M
(+4.7%)
Cap. Flow
+$8.57M
Cap. Flow
% of AUM
3.45%
Top 10 Holdings %
Top 10 Hldgs %
35.47%
Holding
513
New
48
Increased
267
Reduced
44
Closed
122
Top Buys
| 1 |
iQIYI
IQ
|
$12.8M |
| 2 |
Amazon
AMZN
|
$3.31M |
| 3 |
uniQure
QURE
|
$3M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
$2.97M |
| 5 |
DexCom
DXCM
|
$2.87M |
Top Sells
| 1 |
Novo Nordisk
NVO
|
$3.65M |
| 2 |
Tesla
TSLA
|
$3.64M |
| 3 |
Procter & Gamble
PG
|
$3.53M |
| 4 |
Nike
NKE
|
$3.17M |
| 5 |
CVS Health
CVS
|
$2.99M |
Sector Composition
| 1 | Technology | 35.23% |
| 2 | Healthcare | 25.2% |
| 3 | Consumer Discretionary | 20.47% |
| 4 | Communication Services | 8.05% |
| 5 | Financials | 3.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
251
Theravance Biopharma
TBPH
$692M
| $7.67K | ﹤0.01% |
684
-32
| -4% | -$359 |
|
|
BCYC
252
Bicycle Therapeutics
BCYC
$498M
| $7.67K | ﹤0.01% |
259
+20
| +8% | +$592 |
|
253
Sana Biotechnology
SANA
$724M
| $7.66K | ﹤0.01% |
1,938
+157
| +9% | +$620 |
|
254
Anavex Life Sciences
AVXL
$822M
| $7.33K | ﹤0.01% |
792
+62
| +8% | +$574 |
|
255
4D Molecular Therapeutics
FDMT
$294M
| $7.31K | ﹤0.01% |
329
+26
| +9% | +$577 |
|
256
Mirum Pharmaceuticals
MIRM
$3.73B
| $7.29K | ﹤0.01% |
374
+29
| +8% | +$566 |
|
257
Merus
MRUS
$5.05B
| $7.29K | ﹤0.01% |
471
+42
| +10% | +$650 |
|
|
ALLK
258
DELISTED
Allakos
ALLK
| $7.28K | ﹤0.01% |
865
+351
| +68% | +$2.96K |
|
259
ANI Pharmaceuticals
ANIP
$2.03B
| $7.16K | ﹤0.01% |
+178
| New | +$7.16K |
|
260
Seres Therapeutics
MCRB
$170M
| $7.08K | ﹤0.01% |
1,265
+103
| +9% | +$577 |
|
|
ITOS
261
DELISTED
iTeos Therapeutics
ITOS
| $7.05K | ﹤0.01% |
361
+28
| +8% | +$547 |
|
|
DADA
262
DELISTED
Dada Nexus
DADA
| $6.97K | ﹤0.01% |
+1,000
| New | +$6.97K |
|
263
RAPT Therapeutics
RAPT
$193M
| $6.83K | ﹤0.01% |
345
+67
| +24% | +$1.33K |
|
264
Schrodinger
SDGR
$1.41B
| $6.54K | ﹤0.01% |
350
| – | – |
|
265
Tango Therapeutics
TNGX
$705M
| $6.5K | ﹤0.01% |
+896
| New | +$6.5K |
|
266
Exact Sciences
EXAS
$9.14B
| $6.34K | ﹤0.01% |
128
| – | – |
|
267
Castle Biosciences
CSTL
$677M
| $6.31K | ﹤0.01% |
268
+22
| +9% | +$518 |
|
|
ME
268
DELISTED
23andMe Holding Co. Class A Common Stock
ME
| $6.29K | ﹤0.01% |
2,913
+481
| +20% | +$1.04K |
|
269
Repare Therapeutics
RPTX
$73.9M
| $6.27K | ﹤0.01% |
426
+33
| +8% | +$485 |
|
270
Coherus Oncology, Inc. Common Stock
CHRS
$145M
| $6.26K | ﹤0.01% |
790
+62
| +9% | +$491 |
|
271
Aurinia Pharmaceuticals
AUPH
$1.55B
| $6.24K | ﹤0.01% |
1,444
+116
| +9% | +$501 |
|
272
Editas Medicine
EDIT
$228M
| $6.19K | ﹤0.01% |
698
+54
| +8% | +$479 |
|
273
Wave Life Sciences
WVE
$1.21B
| $6.18K | ﹤0.01% |
883
+70
| +9% | +$490 |
|
274
Dyne Therapeutics
DYN
$1.9B
| $6.14K | ﹤0.01% |
530
+46
| +10% | +$533 |
|
|
275
Procter & Gamble
PG
$368B
| $6.06K | ﹤0.01% |
40
-23,300
| -100% | -$3.53M |
|